Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer - sprookjes - yvandenbroek - TriplyDB

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

http://www.wikidata.org/entity/Q24625197

about

PDX1 associated therapy in translational medicine Whole Tumor Antigen Vaccines: Where Are We?Novel Furin Inhibitors with Potent Anti-infectious Activity Dysregulation of TGFβ1 Activity in Cancer and Its Influence on the Quality of Anti-Tumor Immunity Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma.Repression of liver colorectal metastasis by the serpin Spn4A a naturally occurring inhibitor of the constitutive secretory proprotein convertases.Proprotein convertase inhibition: Paralyzing the cell's master switches.Effect of survivin on tumor growth of colorectal cancer in vivo.Generation and characterization of non-competitive furin-inhibiting nanobodies.Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma.Phase 1 Trial of Bi-shRNA STMN1 BIV in Refractory Cancer.Design of Effective Primary MicroRNA Mimics With Different Basal Stem Conformations.Preclinical Justification of pbi-shRNA EWS/FLI1 Lipoplex (LPX) Treatment for Ewing's Sarcoma.T-cell-expressed proprotein convertase FURIN inhibits DMBA/TPA-induced skin cancer development.Myeloid cell expressed proprotein convertase FURIN attenuates inflammation.The proprotein convertase furin is required to maintain viability of alveolar rhabdomyosarcoma cells.siRNA and cancer immunotherapy.Proprotein convertases subtilisin/kexin type 9, an enzyme turned escort protein: hepatic and extra hepatic functions.Insights into the Transforming Growth Factor-β Signaling Pathway in Cutaneous Melanoma.Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.Therapeutic uses of furin and its inhibitors: a patent review.The Role of the Immune System in Ovarian Cancer and Implications on Therapy.A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences.Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions.Pancreatic cancer actionable genes in precision medicine and personalized surgery.Keratin 17 is co-expressed with 14-3-3 sigma in oral carcinoma in situ and squamous cell carcinoma and modulates cell proliferation and size but not cell migration.Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines.Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.Prodomain of the proprotein convertase subtilisin/kexin Furin (ppFurin) protects from tumor progression and metastasis.Preclinical Biodistribution and Safety Evaluation of a pbi-shRNA STMN1 Lipoplex after Subcutaneous Delivery.The proprotein convertase furin in tumour progression.Gli1, a potential regulator of esophageal cancer stem cell, is identified as an independent adverse prognostic factor in esophageal squamous cell carcinoma.Immune response and survival of refractory cancer patients who received TGF-β2 antisense/GM-CSF gene modified autologous tumor cell (TAG) vaccine.The Plasma Level of Proprotein Convertase FURIN in Patients with Suspected Infection in the Emergency Room: A Prospective Cohort Study.Three-year Follow up of GMCSF/bi-shRNA(furin) DNA-transfected Autologous Tumor Immunotherapy (Vigil) in Metastatic Advanced Ewing's Sarcoma.Cancer targeting vaccines: surrogate measures of activity.Knockdown and replacement therapy mediated by artificial mirtrons in spinocerebellar ataxia 7.Ewing's Sarcoma: Development of RNA Interference-Based Therapy for Advanced Disease.

P2860

Q26744079-B57E02C8-93B3-4796-AC00-015B6F3DBAFE Q26783866-89FF44B1-5214-4444-ACBB-4D8A90F3D2B9 Q27700845-CE4D9949-4382-4AA7-B7F1-C521E4797952 Q28075996-C899F6D3-90C5-4593-A2D1-2EDDD764D891 Q30412300-CD7430B9-92A9-411D-ABEE-515C9F2CA7CF Q34100905-DADACC1D-5F7B-4E4A-927F-0745FD9E4895 Q36358957-4CAEB31D-5E00-4370-A3EB-71BF0F3F156D Q36375407-5FFDF27D-2993-41FC-AAAF-C96F1ABE7ACF Q36533737-EA1BDB68-FFDE-4C62-B531-BE4A1F09FFD1 Q36694820-90A1CB79-3C32-4DDE-AC29-747481F2E1BB Q36756669-2B3C6F7F-8152-4D16-8B2B-D0C34D4370BC Q36756699-8069FB38-5285-47D9-B9E4-DE2532552D3F Q37234566-8D8EA7FB-86C7-48C3-B7B7-33580885A25D Q37256170-A8499A96-C2AB-45BB-AEFC-7E107397EF69 Q37558166-BC7D8ECC-E86D-4CF6-A7B4-8078816F2C0A Q37688070-D7D5B83B-9E96-4A37-9F51-104842CF5E53 Q37718282-D9E8FE09-30E3-491E-AF87-726BA030447C Q38050504-19CBF028-3D54-42B0-8E0B-90A80CE07CB5 Q38109960-2FDE2643-5BB7-4F36-BFC5-3D5223E23B53 Q38110273-894A4B6A-CB6B-465E-B2B6-A8CA292617BD Q38118762-5F1754A9-AD70-44E8-A1E1-B233A5E8D37F Q38181359-C5CADF28-60EE-4DBA-933F-3ACC6BD6950B Q38309128-810360CB-C05B-40DD-803F-7333E4E6DFC6 Q38715211-2101D68A-73E6-4304-9B01-92B24DB8336C Q38815929-298924AA-0C01-4A3D-A537-EC8A7991E71B Q38828624-B640C2E9-7859-4A90-9513-183A638D04E0 Q38884916-83E70146-E631-4D69-B209-76DC3F6FB568 Q38903950-7FC6F500-BD65-4D71-AD7F-72743CE5EEFD Q38936958-2E7CB383-4D8C-424E-9566-8625F8743F6F Q39002223-2C4965DC-0BFB-4B87-95DF-0DF4487FA33B Q39078284-38D58794-A254-4BAB-B16E-36D3C6A9E8EC Q39213655-BFFF480C-7F82-40F7-B79F-A4E5810F33DA Q39215671-FED19617-ED38-4997-BD43-DCF7A462A517 Q39343598-202E1FB1-E98C-4223-81B1-A8CE4AB353DE Q39456127-548795EB-7702-477D-8138-FC1FDDEF7BA5 Q41011643-2C8008A2-2D86-4066-93F6-050094365954 Q41093026-BFE2143C-6528-422D-9816-19AC70358FCF Q41222516-F423F522-1187-40A6-AC25-8AD0205F7C40 Q41508524-819FB1DE-DD6E-4AB1-9C2A-6518CE1E413F Q42006104-5C3826AC-C077-46DF-A8C4-367A2B2CAE86

P2860

Phase I trial of "bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell" vaccine (FANG) in advanced cancer

http://www.wikidata.org/entity/Q24625197

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@ast

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@en

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@nl

type

label

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@ast

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@en

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@nl

prefLabel

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@ast

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@en

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@nl

P1433

Q24625197-625EBF27-A3B4-47DA-9948-F1CC0B68B64F

P1476

Q24625197-DEC667AE-E386-45ED-83D1-4CDC078A0AD0

P2093

Q24625197-07865C1E-BB48-4CA9-BE17-E6204E8F4E68

Q24625197-0C297B17-3381-4DE3-93D6-14A841B54884

Q24625197-10B70BA4-9DCA-4B6C-A435-95A24C794BB2

Q24625197-10D03A1B-CB65-44D4-81CD-D37096EACA39

Q24625197-14457010-F870-475B-BA2E-532CB58ACFE6

Q24625197-14D41B26-AF5B-4953-92EC-D3E114DE13A7

Q24625197-3F91BBA7-4DFC-472B-9E2A-F5EAA33D15FE

Q24625197-3FF1D636-37DF-4979-A070-8C015AA1ABA6

Q24625197-415FF24E-5C20-426B-8ADF-385256D70286

Q24625197-4FCBE2FC-FA8F-4C94-8347-0BB156C35F4A

P2860

Q24625197-01DE5B11-A4DC-4A60-8470-3FD5D244D90B

Q24625197-041440B1-60DB-4AC2-B415-05C418AA87ED

Q24625197-0E8E460C-0949-4BBF-82F3-90A57E9F1EBE

Q24625197-1752867C-B790-4636-9583-CCB94E3F0954

Q24625197-1D09B27F-1192-45F6-8BD7-075DE2048832

Q24625197-25159919-F4EE-4D4C-9CCF-3F8C12436734

Q24625197-294A6CA7-DD03-4CE8-847E-30FD0BB9BDFF

Q24625197-2C0981B8-45E0-4FB5-924C-E30D4E67C12C

Q24625197-2C0E9383-F3A2-4F3B-B1CC-E8295C987F1E

Q24625197-30487523-D3BD-4A19-890A-8C43D0A1E79D

P304

Q24625197-37E8C968-5164-4DC1-BA08-44A25C0BB107

P31

Q24625197-095BF845-9C0A-4230-8B03-28A3877996F1

P3181

Q24625197-6F5DEA3F-E88B-4C04-B1A3-8DE970C8CD30

P356

Q24625197-EB0EB96D-EBF2-4EBC-9204-BCDB8187E495

P407

Q24625197-DB80477C-15AC-4195-B339-B698DE9B63C8

P433

Q24625197-E7E066A9-7638-46AF-B23E-A7D05CD59D40

P478

Q24625197-625D7F3C-F042-4331-A5B5-2CBFA3B354C9

P577

Q24625197-E429F23D-9B66-405A-B7BA-700584CC37D7

P5875

Q24625197-FF71E36E-2E4C-466A-B636-0FB473F3E22A

P698

Q24625197-CC121EF8-BE65-43C2-BAA3-3E81AB870C6A

P921

Q24625197-955688EF-8FDC-4FDA-804C-C1724F07AACB

Q24625197-9B3DC708-B5EC-4298-B8FD-8F484580E46B

P932

Q24625197-40059F77-5E56-4BF4-8751-13A90D768D39

P3181

P356

P1433

Molecular Therapy

P1476

Phase I trial of "bi-shRNAi(fu ...... cine (FANG) in advanced cancer

@en

P2093

Anton Melnyk

http://www.w3.org/2001/XMLSchema#string

Beena O Pappen

http://www.w3.org/2001/XMLSchema#string

Candice Higgs

http://www.w3.org/2001/XMLSchema#string

Chris M Jay

http://www.w3.org/2001/XMLSchema#string

Connor Phalon

http://www.w3.org/2001/XMLSchema#string

Cynthia Bedell

http://www.w3.org/2001/XMLSchema#string

David M Shanahan

http://www.w3.org/2001/XMLSchema#string

Donald D Rao

http://www.w3.org/2001/XMLSchema#string

F Charles Brunicardi

http://www.w3.org/2001/XMLSchema#string

Fabienne Norvell

http://www.w3.org/2001/XMLSchema#string

P2860

T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

The proprotein convertases furin and PACE4 play a significant role in tumor progression

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Transforming growth factor-beta regulation of immune responses

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers.

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Bidirectional regulation of macrophage function by TGF-beta.

The immune response during acute HIV-1 infection: clues for vaccine development.

Dendritic cell function in vivo during the steady state: a role in peripheral tolerance.

P304

679-86

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3792132

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/MT.2011.269

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51879698

http://www.w3.org/2001/XMLSchema#string

P698

22186789

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

3293620

http://www.w3.org/2001/XMLSchema#string